EM2AI has received a Category 2 Medical Device Licence from the Food and Drug Administration (FDA) of Thailand; a Class B Medical Device Licence from the Food and Drug Administration (FDA) of the Philippines; a Class B Medical Device Licence from the Department of Medical Equipment and Construction (DMEC) of Vietnam; and a Class C Medical Device Licence from the Ministry of Health of Indonesia.
With the licences, EM2AI will now be able to sell and distribute its dental AI solutions in more jurisdictions, says Q&M Dental. “The company understands that EM2AI is actively seeking distributors and potential customers in these jurisdictions as part of its efforts to expand the business.”
Q&M Dental disposed of 51% interest in EM2AI in March 2024, resulting in a decrease in equity interest from 100% to 49%. Hence, Q&M Dental reported in August net other gains of $1.8 million for 1HFY2024 ended June 30, partly from the gain on disposal of EM2AI, as well as compensation from ex-vendors in other operations.
Shares in Q&M Dental opened flat at 28.5 cents on Jan 13. The company’s shares have risen 9.6% over the past year.
